What are the National Comprehensive Cancer Network (NCCN) guidelines for first-line therapy to treat predominantly clear cell renal cell carcinoma (RCC)?

Updated: Jun 08, 2020
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

The 2018 National Comprehensive Cancer Network (NCCN) kidney cancer guideline recommends that for patients with predominantly clear cell cancer, considerations for first-line therapy are best supportive care and one of the following:

  • Pazopanib (category 1, preferred)
  • Sunitinib (category 1, preferred)
  • Bevacizumab + interferon alfa-2b (category 1)
  • Temsirolimus (category 1 for poor-prognosis patients, category 2B for selected patients of other risk groups)
  • Axitinib
  • Cabozantinib (for poor- and intermediate-risk groups)
  • High-dose IL-2 for selected patients (with excellent performance status and normal organ function)
  • Active surveillance for select, asymptomatic patients)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!